Anke Biotech announced that recently, the participating companies Bosheng Ji Pharmaceutical Technology Co., Ltd. and Bosheng Jianke Cell Technology Co., Ltd. received the minutes of the PA3-17 injection phase II communication meeting issued by the Drug Evaluation Center of the State Drug Administration and agreed that the applicant will conduct a critical phase II clinical trial of PA3-17 injection. PA3-17 injection is the world's first CD7-targeted autologous CAR-T cell therapy product independently developed by Bosheng Jianko and approved for clinical trials. It is used to treat recurrent and refractory CD7-positive hematologic lymphatic system malignancies in adults.

Anke Biotech announced that recently, the participating companies Bosheng Ji Pharmaceutical Technology Co., Ltd. and Bosheng Jianke Cell Technology Co., Ltd. received the minutes of the PA3-17 injection phase II communication meeting issued by the Drug Evaluation Center of the State Drug Administration and agreed that the applicant will conduct a critical phase II clinical trial of PA3-17 injection. PA3-17 injection is the world's first CD7-targeted autologous CAR-T cell therapy product independently developed by Bosheng Jianko and approved for clinical trials. It is used to treat recurrent and refractory CD7-positive hematologic lymphatic system malignancies in adults.